About Aviceda Therapeutics
Aviceda Therapeutics is a private company based in Cambridge, Massachusetts. It has reported $173,559,476 raised in seven offerings on Form D since September 2020. Its chief executive is Derek Kunimoto.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 17, 2024 | Nov 22, 2024amended Jan 13, 2025 | $74,999,940of $207.4M target | 17 | $4.4M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| May 17, 2024 | May 31, 2024 | $18,899,969of $27.7M target | 18 | $1.0M | Equity, OptionsRule 506(b) | Form D ↗ |
| May 5, 2023 | May 19, 2023 | $15,610,000fully sold | 11 | $1.4M | EquityRule 506(b) | Form D ↗ |
| Mar 16, 2022 | Mar 28, 2022 | $49,450,983of $79.7M target | 11 | $4.4M | EquityRule 506(b) | Form D ↗ |
| Mar 11, 2022 | Mar 28, 2022 | $8,398,584of $26.2M target | 16 | $524K | EquityRule 506(b) | Form D ↗ |
| Jul 14, 2021 | Aug 12, 2021 | $1,950,000fully sold | 7 | $278K | Debt, Convertible NotesRule 506(b) | Form D ↗ |
| Feb 26, 2020 | Sep 16, 2020 | $4,250,000fully sold | 15 | $283K | convertible notesRule 506(b) | Form D ↗ |
| Total, seven offerings | $173,559,476 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Aviceda Therapeutics's Form D filed Jan 13, 2025.
Earlier filings also listed Patrick Johnson (director, last listed May 2024), Paul Vukelic (director, last listed May 2023), Ross Darwin (director, last listed Mar 2022), Robert Kniaz (director, last listed Mar 2022), Mariusz Gralewski (director, last listed Mar 2022), Kyrylo Bigay (president and director, last listed Mar 2022) and Dmytro Voloshyn (director, last listed Mar 2022).